NLRP3 and cryopyrin-associated periodic syndrome: In 2022, the inhibitor passed a phase 1 clinical trial followed by an ongoing phase 2 study for safety and clinical activity in patients with cryopyrin-associated periodic syndrome (CAPS), a condition caused by an NLRP3 gene mutation (NCT05812781).